Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment

Journal of Steroid Biochemistry and Molecular Biology

Volumn 139, Issue , 2014, Pages 88-97

  Ono, Yoshiyuki ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Alfacalcidol; Calcitriol; CYP24A1; Eldecalcitol; Osteoporosis; Vitamin D binding protein; Vitamin D receptor

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CARRIER PROTEIN; ELDECALCITOL; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

BONE DENSITY; DRUG EFFICACY; DRUG SAFETY; FRACTURE; OSTEOPOROSIS; REVIEW;

1Α,2Β,25-TRIHYDROXYVITAMIN D(3); 1Α,25-DIHYDROXY-2Β-(3-HYDROXYPROPOXY)VITAMIN D(3); 2-METHYLENE-19-NOR-(20S)-1Α,25-DIHYDROXYVITAMIN D(3); 2MD; ALFACALCIDOL; CALCITRIOL; CMAX; CYP24A1; DBP; ED-138; ED-71; ELDECALCITOL; FGF23; FIBROBLAST GROWTH FACTOR; H-BOND; HYDROGEN BOND; MAXIMUM DRUG CONCENTRATION; NAPIIIB; NMR; NUCLEAR MAGNETIC RESONANCE; OSTEOPOROSIS; PARATHYROID HORMONE; PTH; QOL; QUALITY OF LIFE; RANKL; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KB LIGAND; RETINOID X RECEPTOR; RXR; S1PR2; SPHINGOSINE-1-PHOSPHATE RECEPTOR 2; TRANSIENT RECEPTOR POTENTIAL VANILLOID 6; TRPV6; TYPE IIB SODIUM-DEPENDENT PHOSPHATE CO-TRANSPORTER; VDR; VDRE; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; VITAMIN D RESPONSIVE ELEMENT.;

ANIMALS; BINDING SITES; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, MOLECULAR; OSTEOPOROSIS; PROTEIN BINDING; RECEPTORS, CALCITRIOL; STRUCTURE-ACTIVITY RELATIONSHIP; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84886734747     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.10.007     Document Type: Review

References (89)

1. L.J. Melton, E.A. Chrischilles, C. Cooper, A.W. Lane, and B.L. Riggs Perspective how many women have osteoporosis? Journal of Bone and Mineral Research 7 1992 1005 1010
2. R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, and A. Tosteson Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 Journal of Bone and Mineral Research 22 2007 465 475
3. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis Calcified Tissue International 54 1994 370 376
4. 3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study Endocrine Journal 43 1996 211 220
5. Y. Ishida, and S. Kawai Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study American Journal of Medicine 117 2004 549 555
6. M.W. Tilyard, G.F.S. Spears, J. Thomson, and S. Dovey Treatment of postmenopausal osteoporosis with calcitriol or calcium New England Journal of Medicine 326 1992 357 362
7. 3 analogs bearing a hydroxyalkyl group at the 2β-position Chemical and Pharmaceutical Bulletin 41 1993 1111 1113
8. 3 analogs substituted at the 2β-position and their preventive effects on bone mineral loss in ovariectomized rats Chemical and pharmaceutical Bulletin 45 1997 1626 1630
9. N. Kubodera, K. Sato, and Y. Nishii Characteristics of 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy)-calcitriol (ED-71) D. Feldman, F.H. Glorieux, J.W. Pike, Vitamin D 1997 Academic Press New York 1071 1086
10. N. Kubodera Development of OCT and ED-71 F. David, J.W. Pike, F.H. Glorieux, Vitamin D 2nd ed. 2005 Academic Press Burlington 1525 1541
11. 3 analogs Current Bioactive Compounds 2 2006 301 315
12. N. Kubodera D-hormone derivatives for the treatment of osteoporosis: from alfacalcidol to eldecalcitol Mini Reviews in Medicinal Chemistry 9 2009 1416 1422
13. T. Matsumoto, T. Takano, S. Yamakido, F. Takahashi, and N. Tsuji Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism Journal of Steroid Biochemistry and Molecular Biology 121 2010 261 264
14. M. Ito, T. Nakamura, M. Fukunaga, M. Shiraki, and T. Matsumoto Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT Bone 49 2011 328 334
15. 3 analog, eldecalcitol, prevents the risk of osteoporotic fractures - a randomized, active comparator, double-blind study Bone 49 2011 605 612
16. H. Hagino, T. Takano, M. Fukunaga, M. Shiraki, T. Nakamura, and T. Matsumoto Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis Journal of Bone and Mineral Metabolism 31 2013 183 189
17. 3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats Calcified Tissue International 54 1994 142 149
18. Y. Uchiyama, Y. HiguchI, S. Takeda, T. Masaki, A. Shira-ishi, K. Sato, N. Kubodera, K. Ikeda, and E. Ogata ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis Bone 30 2002 582 588
19. T. Matsumoto, T. Miki, H. Hagino, T. Sugimoto, S. Okamoto, T. Hirota, Y. Tanigawara, Y. Hayashi, M. Fukunaga, M. Shiraki, and T. Nakamura A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial Journal of Clinical Endocrinology and Metabolism 90 2005 5031 5036
20. N. Kubodera, N. Tsuji, Y. Uchiyama, and K. Endo A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients Journal of Cellular Biochemistry 88 2003 286 289
21. 3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects Journal of Steroid Biochemistry and Molecular Biology 103 2007 584 586
22. N. Kubodera, and F. Takahashi Analogs for the treatment of osteoporosis F. David, J.W. Pike, J.S. Adams, Vitamin D 3rd ed. 2011 Academic Press San Diego 1489 1496
23. 3 in normal and uraemic men Nephrology Dialysis Transplantation 17 2002 829 842
24. 3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) null mouse Endocrinology 146 2005 825 834
25. G. Jones, D.E. Prosser, and M. Kaufmann 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D Archives of Biochemistry and Biophysics 523 2012 9 18
26. R.F. Chun New perspectives on the vitamin D binding protein Cell Biochemistry and Function 30 2012 445 456
27. R.M. Evans The steroid and thyroid hormone receptor superfamily Science 240 1988 889 895
28. R.C.J. Ribeiro, P.J. Kushner, and J.D. Baxter The nuclear hormone receptor gene superfamily Annual Review of Medicine 46 1995 443 453
29. 3 (eldecalcitol) is a potent regulator of calcium and phosphate metabolism Calcified Tissue International 89 2011 372 378
30. A.J. Brown, F. Zhang, and C.S. Ritter The vitamin D analog ED-71 is a potent regulator of intestinal phosphate absorption and Napi-IIb Endocrinology 153 2012 5150 5156
31. H. Takasu, A. Sugita, Y. Uchiyama, N. Katagiri, M. Okazaki, E. Ogata, and K. Ikeda c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs Journal of Clinical Investigation 116 2006 528 535
32. S. Harada, T. Mizoguchi, Y. Kobayashi, Y. Nakamichi, S. Takeda, S. Sakai, F. Takahashi, H. Saito, H. Yasuda, N. Udagawa, T. Suda, and N. Takahashi Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone Journal of Bone and Mineral Research 27 2012 461 473
33. T. Suda, F. Takahashi, and N. Takahashi Bone effects of vitamin D - discrepancies between in vivo and in vitro studies Archives of Biochemistry and Biophysics 523 2012 22 29
34. J. Kikuta, S. Kawamura, F. Okiji, M. Shirazaki, S. Sakai, H. Saito, and M. Ishii Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D Proceedings of the National Academy of Sciences of the United States of America 110 2013 7009 7013
35. H. Saito, S. Takeda, and N. Amizuka Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone Journal of Steroid Biochemistry and Molecular Biology 136 2013 178 182
36. 3 (24-hydroxylated ED-71) Steroids 66 2001 267 276
37. 3 (ED-71) Steroids 71 2006 529 540
38. A.F. Stepan, V. Mascitti, K. Beaumont, and A.S. Kalgutkar Metabolism-guided drug design Medicinal Chemistry Communications 4 2013 631 652
39. 3 derivative Japanese Pharmacology and Therapeutics 39 2011 261 274
40. Y. Ikeda, Y. Kumagai, T. Arinaga, M. Sata, T. Hiroki, K. Miyata, and A. Ohnishi Open-label, multicentre, single dose study of eldecalcitol pharmacokinetics in patients with impaired liver function Japanese Pharmacology and Therapeutics 39 2011 287 297
41. C.S. Ritter, and A.J. Brown Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D-binding protein and resistance to metabolism Journal of Cellular Biochemistry 112 2011 1348 1352
42. A.J. Annalora, D.B. Goodin, W.X. Hong, Q. Zhang, E.F. Johnson, and C.D. Stout Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism Journal of Molecular Biology 396 2010 441 451
43. C. Bergwitz, and H. Jüppner Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23 Annual Review of Medicine 61 2010 91 104
44. K. Miyata, Y. Ohba, M. Abe, K. Terao, T. Kawanishi, and A. Ohnishi Effects of eldecalcitol on the pharmacokinetics of the CYP3A4 substrate, simvastatin - double blind, randomized, placebo-controlled, parallel group comparative study in healthy male volunteers Japanese Pharmacology and Therapeutics 39 2011 275 285
45. K. Miyata, M. Abe, K. Terao, T. Kawanishi, N. Tsuji, M. Shiraki, T. Nakamura, T. Matsumoto, and Y. Tanigawara Pharmacokinetics of eldecalcitol in primary osteoporosis patients - randomized, double-blind, multicentre, long-term phase III clinical study Japanese Pharmacology and Therapeutics 39 2011 299 307
46. 3 (ED-71) Journal of Steroid Biochemistry and Molecular Biology 103 2007 222 226
47. A.M. Kissmeyer, I.S. Mathiasen, S. Latini, and L. Binderup Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP) Endocrine 3 1995 263 266
48. C. Verboven, A. Rabijns, M. De Maeyer, H. Van Baelen, R. Bouillon, and C. De Ranter A structural basis for the unique binding features of the human vitamin D-binding protein Nature Structural Biology 9 2002 131 136
49. 3 selectively induces bone formation Proceedings of the National Academy of Sciences of the United States of America 99 2002 13487 13491
50. H.F. DeLuca, W. Bedale, N. Binkley, J.C. Gallagher, M. Bolognese, M. Peacock, J. Aloia, M. Clagett-Dame, and L. Plum The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial Journal of Bone and Mineral Research 26 2011 538 545
51. M. Choi, and M. Makishima Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands Expert Opinion on Therapeutic Patents 19 2009 593 606
52. W.H. Okamura, G.D. Zhu, D.K. Hill, R.J. Thomas, K. Ringe, D.B. Borchardt, A.W. Norman, and L.J. Mueller Synthesis and NMR studies of 13C-labeled vitamin D metabolites Journal of Organic Chemistry 67 2002 1637 1650
53. N. Rochel, J.M. Wurtz, A. Mitschler, B. Klaholz, and D. Moras The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand Molecular Cell 5 2000 173 179
54. G. Tocchini-Valentini, N. Rochel, J.M. Wurtz, A. Mitschler, and D. Moras Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands Proceedings of the National Academy of Sciences of the United States of America 98 2001 5491 5496
55. G. Tocchini-Valentini, N. Rochel, J.M. Wurtz, and D. Moras Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification Journal of Medicinal Chemistry 47 2004 1956 1961
56. 3 hormone analogues and a LXXLL-containing coactivator peptide Biochemistry 43 2004 4101 4110
57. G. Eelen, L. Verlinden, N. Rochel, F. Claessens, P. De Clercq, M. Vandewalle, G. Tocchini-Valentini, D. Moras, R. Bouillon, and A. Verstuyf Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction Molecular Pharmacology 67 2005 1566 1573
58. 3 with selected 2α-substituted analogues Journal of Medicinal Chemistry 49 2006 5199 5205
59. 3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations Archives of Biochemistry and Biophysics 460 2007 161 165
60. F. Ciesielski, N. Rochel, and D. Moras Adaptability of the vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation Journal of Steroid Biochemistry and Molecular Biology 103 2007 235 242
61. N. Rochel, S. Hourai, X. Pérez-García, A. Rumbo, A. Mourino, and D. Moras Crystal structure of the vitamin D nuclear receptor ligand binding domain in complex with a locked side chain analog of calcitriol Archives of Biochemistry and Biophysics 460 2007 172 176
62. S. Hourai, L.C. Rodrigues, P. Antony, B. Reina-San-Martin, F. Ciesielski, B.C. Magnier, K. Schoonjans, A. Mouriño, N. Rochel, and D. Moras Structure-based design of a superagonist ligand for the vitamin D nuclear receptor Chemistry and Biology 15 2008 383 392
63. 3 analogue YR301 Acta Crystallographica Section F: Structural Biology and Crystallization Communications 64 2008 970 973
64. 3 analogs: synthesis, biological evaluation, and crystal structure Bioorganic and Medicinal Chemistry 16 2008 6949 6964
65. M. Nakabayashi, S. Yamada, N. Yoshimoto, T. Tanaka, M. Igarashi, T. Ikura, N. Ito, M. Makishima, H. Tokiwa, H.F. DeLuca, and M. Shimizu Crystal structures of rat vitamin D receptor bound to adamantyl vitamin D analogs: structural basis for vitamin D receptor antagonism and partial agonism Journal of Medicinal Chemistry 51 2008 5320 5329
66. 3 analogs stabilize helix 12 of the vitamin D receptor Chemistry and Biology 15 2008 1029 1034
67. Y. Inaba, N. Yoshimoto, Y. Sakamaki, M. Nakabayashi, T. Ikura, H. Tamamura, N. Ito, M. Shimizu, and K. Yamamoto A new class of vitamin D analogues that induce structural rearrangement of the ligand-binding pocket of the receptor Journal of Medicinal Chemistry 52 2009 1438 1449
68. 3-26,23-lactone Acta Crystallographica Section D 66 2010 918 926
69. 3 Journal of Medicinal Chemistry 53 2010 1159 1171
70. N. Rochel, S. Hourai, and D. Moras Crystal structure of hereditary vitamin D-resistant rickets-associated mutant H305Q of vitamin D nuclear receptor bound to its natural ligand Journal of Steroid Biochemistry and Molecular Biology 121 2010 84 87
71. 3: recovery of vitamin D receptor agonistic activity Journal of Steroid Biochemistry and Molecular Biology 121 2010 146 150
72. Y. Kawasaki, and E. Freire Finding a better path to drug selectivity Drug Discovery Today 16 2011 985 990
73. N.A. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chemical Research in Toxicology 24 2011 1420 1456
74. R. Zhang, and F. Monsma The importance of drug-target residence time Current Opinion in Drug Discovery and Development 12 2009 488 496
75. R. Zhang, and F. Monsma Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs Expert Opinion on Drug Discovery 5 2010 1023 1029
76. P.J. Tummino, and R.A. Copeland Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 47 2008 5481 5492
77. P.A. Glossop, C.A.L. Watson, D.A. Price, M.E. Bunnage, D.S. Middleton, A. Wood, K. James, D. Roberts, R.S. Strang, M. Yeadon, C. Perros-Huguet, N.P. Clarke, M.A. Trevethick, I. Machin, E.F. Stuart, S.M. Evans, A.C. Harrison, D.A. Fairman, B. Agoram, J.L. Burrows, N. Feeder, C.K. Fulton, B.R. Dillon, D.A. Entwistle, and F.J. Spence Inhalation by design: novel tertiary amine muscarinic M3 receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease Journal of Medicinal Chemistry 54 2011 6888 6904
78. 3 derivative, on calcium metabolism Biochemical and Biophysical Research Communications 163 1989 1444 1449
79. R. Lumry, and S. Rajender Enthalpy-entropy compensation phenomena in water solutions of proteins and small molecules: a ubiquitous properly of water Biopolymers 9 1970 1125 1227
80. Y. Kato, M.M. Conn, and J. Rebek Hydrogen bonding in water using synthetic receptors Proceedings of the National Academy of Sciences of the United States of America 92 1995 1208 1212
81. M.V. Rekharsky, T. Mori, C. Yang, Y.H. Ko, N. Selvapalam, H. Kim, D. Sobransingh, A.E. Kaifer, S. Liu, L. Isaacs, W. Chen, S. Moghaddam, M.K. Gilson, K. Kim, and Y. Inoue A synthetic host-guest system achieves avidin-biotin affinity by overcoming enthalpy-entropy compensation Proceedings of the National Academy of Sciences of the United States of America 104 2007 20737 20742
82. H. Sorensen, L. Binderup, M.J. Calverley, L. Hoffmeyer, and N.R. Andersen In vitro metabolism of calcipotriol (MC 903), a vitamin D analogue Biochemical Pharmacology 39 1990 391 393
83. S. Masuda, V. Byford, R. Kremer, H.L.J. Makin, N. Kubodera, Y. Nishii, A. Okazaki, T. Okano, T. Kobayashi, and G. Jones In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma, and keratinocyte cell lines Journal of Biological Chemistry 271 1996 8700 8708
84. 3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels Xenobiotica 29 1999 603 613
85. L. Dukas, H.A. Bischoff, L.S. Lindpaintner, E. Schacht, B.D. Birkner, T.N. Damm, B. Thalmann, and H.B. Stähelin Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily Journal of the American Geriatrics Society 52 2004 230 236
86. J.D. Ringe, P. Farahmand, and E. Schacht Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients Rheumatology International 33 2013 637 643
87. J.C. Gallagher The effects of calcitriol on falls and fractures and physical performance tests Journal of Steroid Biochemistry and Molecular Biology 89-90 2004 497 501
88. 3 enhances fast-myosin heavy chain expression in differentiated C2C12 myoblasts Cell Biology International 36 2012 441 447
89. A.W. Norman, and R. Bouillon Vitamin D nutritional policy needs a vision for the future Experimental Biology and Medicine 235 2010 1034 1045